CTNNB1 Alternation Is a Potential Biomarker for Immunotherapy Prognosis in Patients With Hepatocellular Carcinoma.

ABSTRACT:

Background

The emergence of immune checkpoint inhibitors (ICIs) marks the beginning of a new era of immunotherapy for hepatocellular carcinoma (HCC), however, not all patients respond successfully to this treatment. A major challenge for HCC immunotherapy is the development of ways to screen for those patients that would benefit from this type of treatment and determine the optimal treatment plan for individual patients. Therefore, it is important to find a biomarker which allows for the stratification of HCC patients, which distinguishes responders from non-responders, thereby further improving the clinical benefits for those undergoing immunotherapy.

Methods

We used univariate and multivariate Cox risk proportional regression models to evaluate the relationship between non

SUBMITTER: Chen L 

PROVIDER: S-EPMC8581472 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature